SMTI

+ Watchlist + Portfolio

Sanara MedTech Inc.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $34.88
52-Week Range: $16.05 – $35.34
Market Cap: $320.20M
P/E (TTM): —
EPS (TTM): -0.04
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 40.34
PEG Ratio: —
Return on Equity: -1.32%
Return on Assets: 7.64%
Gross Margin: 93.03%
Operating Margin: 6.33%
Profit Margin: -29.15%
Current Ratio: 2.58
Debt/Equity: 6.12
Total Debt: $48.53M
Free Cash Flow: $5.70M
Revenue Growth: 9.00%
Earnings Growth: —
Enterprise Value: $353.30M

SMTI Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$45.84M	$64.99M	$86.67M	$103.12M
Cost of Revenue	$6.36M	$7.85M	$8.14M	$7.52M
Gross Profit	$39.48M	$57.14M	$78.53M	$95.60M
Research & Development	$3.37M	$4.13M	$2.83M	$5.07M
Selling, General & Admin	$45.98M	$56.99M	$71.67M	$78.72M
Operating Expenses	$51.71M	$64.80M	$77.29M	$86.45M
Operating Income	-$12.23M	-$7.67M	$1.24M	$9.15M
EBITDA	-$11.57M	-$289.09K	$6.11M	$10.31M
Pretax Income	-$13.94M	-$4.44M	-$1.94M	-$393.12K
Income Tax	-$5.84M	$0.00	—	—
Net Income	-$7.94M	-$4.30M	-$9.66M	-$37.56M
Diluted EPS	-1.00	-0.52	-1.14	-4.36
Diluted Shares	7.91M	8.28M	8.48M	8.62M

SMTI Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$8.96M	$5.15M	$15.88M	$16.58M
Receivables	$7.00M	$8.53M	$13.55M	$12.00M
Inventory	$3.55M	$4.72M	$2.75M	$3.95M
Current Assets	$20.62M	$19.01M	$33.31M	$33.54M
Total Assets	$61.04M	$73.87M	$88.09M	$72.94M
Current Liabilities	$12.81M	$13.77M	$15.29M	$18.63M
Long-Term Debt	—	$9.11M	$30.69M	$45.97M
Total Debt	$819.22K	$11.79M	$32.29M	$48.19M
Total Liabilities	$19.32M	$29.28M	$49.18M	$67.01M
Retained Earnings	-$23.39M	-$28.04M	-$37.78M	-$75.30M
Shareholders' Equity	$41.83M	$44.83M	$39.40M	$5.94M
Working Capital	$7.81M	$5.24M	$18.02M	$14.92M
Net Debt	—	$4.55M	$14.81M	$29.39M

SMTI Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$5.55M	-$3.25M	-$23.78K	$6.79M
Capital Expenditure	-$747.01K	-$265.25K	-$229.30K	-$4.65M
Free Cash Flow	-$6.30M	-$3.51M	-$253.08K	$2.14M
Depreciation & Amortisation	$2.37M	$3.68M	$4.92M	$3.95M
Stock-Based Compensation	$2.70M	$3.44M	$4.44M	$5.15M
Investing Cash Flow	-$3.51M	-$10.21M	-$6.61M	-$14.97M
Financing Cash Flow	-$627.35K	$9.64M	$17.37M	$8.89M
Net Change in Cash	-$9.69M	-$3.81M	$10.73M	$700.56K

SMTI Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$23.43M	$25.80M	$26.33M	$27.55M	$27.80M	$28.14M
Cost of Revenue	$1.83M	$1.94M	$1.87M	$1.87M	$1.92M	$1.98M
Gross Profit	$21.60M	$23.87M	$24.46M	$25.67M	$25.87M	$26.16M
Research & Development	$950.36K	$1.06M	$1.03M	$2.04M	$759.59K	$1.15M
Selling, General & Admin	$19.13M	$19.63M	$19.88M	$20.08M	$21.88M	$22.60M
Operating Expenses	$20.77M	$21.38M	$21.52M	$22.78M	$23.23M	$24.38M
Operating Income	$825.53K	$2.49M	$2.94M	$2.89M	$2.65M	$1.78M
EBITDA	$1.82M	$3.41M	$3.69M	$1.39M	$2.78M	$2.02M
Pretax Income	-$620.57K	$500.26K	$834.49K	-$1.11M	$397.69K	-$411.14K
Net Income	-$3.53M	-$2.01M	-$30.41M	-$1.61M	$458.96K	-$452.86K
Diluted EPS	-0.41	-0.23	-3.52	-0.19	0.05	-0.05
Diluted Shares	8.57M	8.61M	8.94M	8.47M	8.99M	8.66M

SMTI Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$20.69M	$16.96M	$14.94M	$16.58M	$13.59M	$15.42M
Receivables	$11.90M	$12.00M	$12.09M	$12.00M	$13.62M	$12.57M
Inventory	$3.16M	$3.51M	$3.39M	$3.95M	$3.12M	$3.46M
Current Assets	$36.84M	$33.67M	$31.23M	$33.54M	$31.20M	$32.20M
Total Assets	$96.38M	$98.77M	$71.09M	$72.94M	$69.28M	$69.15M
Current Liabilities	$13.28M	$14.88M	$17.36M	$18.63M	$13.70M	$12.49M
Long-Term Debt	$43.40M	$44.22M	$45.09M	$45.97M	$46.23M	$46.48M
Total Debt	$44.72M	$45.45M	$47.39M	$48.19M	$48.37M	$48.53M
Total Liabilities	$59.71M	$63.38M	$64.95M	$67.01M	$62.26M	$61.21M
Retained Earnings	-$41.31M	-$43.29M	-$73.69M	-$75.30M	-$74.50M	-$74.89M
Shareholders' Equity	$36.67M	$35.40M	$6.15M	$5.94M	$7.03M	$7.94M
Working Capital	$23.56M	$18.79M	$13.87M	$14.92M	$17.50M	$19.71M
Net Debt	$22.71M	$27.26M	$30.15M	$29.39M	$32.63M	$31.06M

SMTI Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$2.00M	$2.66M	$2.18M	$3.95M	-$2.47M	$2.04M
Capital Expenditure	-$1.72M	-$1.78M	-$1.06M	-$82.16K	-$43.77K	-$5.28K
Free Cash Flow	-$3.72M	$879.20K	$1.12M	$3.86M	-$2.51M	$2.03M
Depreciation & Amortisation	$1.12M	$1.11M	$1.04M	$668.40K	$587.25K	$619.11K
Stock-Based Compensation	$1.30M	$1.44M	$1.23M	$1.18M	$1.03M	$1.50M
Investing Cash Flow	-$5.18M	-$3.93M	-$3.42M	-$2.45M	-$43.77K	-$5.28K
Financing Cash Flow	$11.99M	-$2.47M	-$774.75K	$139.43K	-$475.22K	-$206.48K
Net Change in Cash	$4.81M	-$3.73M	-$2.02M	$1.64M	-$2.98M	$1.83M

Market Snapshot

About

Sanara MedTech is a medical technology company focused on developing and commercializing products for wound care and skincare. The company offers advanced wound care dressings, surgical solutions, and dermatological products for healthcare providers and patients. Sanara markets its products through distribution partners and direct sales to hospitals, wound care centers, and physicians.